Search results
- 1.0564874 - MBÚ 2023 RIV US eng J - Journal Article
Wasserbauer, M. - Hlava, S. - Drábek, J. - Šťovíček, J. - Minaříková, P. - Nedbalová, L. - Drasar, T. - Zadorová, Z. - Dolina, J. - Konečný, S. - Kojecky, V. - Koželuhová, J. - Černíková, P. - Pichlerová, D. - Kučerová, B. - Coufal, Štěpán - Keil, R.
Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
PLoS ONE. Roč. 17, 8 August (2022), č. článku e0271299. ISSN 1932-6203. E-ISSN 1932-6203
Institutional support: RVO:61388971
Keywords : Adalimumab * Biosimilar Pharmaceuticals * Colitis * Ulcerative * Crohn Disease * Humans * Inflammatory Bowel Diseases * Prospective Studies * Remission Induction * Treatment Outcome
OECD category: General and internal medicine
Impact factor: 3.7, year: 2022
Method of publishing: Open access
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271299
Permanent Link: https://hdl.handle.net/11104/0336441 - 2.0556729 - ÚI 2023 RIV NO eng J - Journal Article
Lukáš, M. - Kolář, M. - Reissigová, Jindra - Ďuricová, D. - Machková, N. - Hrubá, V. - Lukáš, M. - Vašátko, M. - Jirsa, J. - Pudilová, K. - Malíčková, K.
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts.
Scandinavian Journal of Gastroenterology. Roč. 57, č. 7 (2022), s. 814-824. ISSN 0036-5521. E-ISSN 1502-7708
Institutional support: RVO:67985807
Keywords : Crohn’s disease * adalimumab * biosimilar
OECD category: Statistics and probability
Impact factor: 1.8, year: 2022
Method of publishing: Open access
http://dx.doi.org/10.1080/00365521.2022.2041082
Permanent Link: http://hdl.handle.net/11104/0330887File Download Size Commentary Version Access 0556729-afin.pdf 5 2 MB OA CC BY 4.0 Author´s preprint open-access